{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:38:01Z","timestamp":1791333481766,"version":"4.3.1"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Research to Prevent Blindness, New York, NY - unrestricted grant to the Department of Ophthalmology at the University of Iowa Hospitals and Clinics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1038\/s41433-021-01904-4","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T06:03:35Z","timestamp":1641276215000},"page":"1500-1501","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The role of teprotumumab in chronic, clinically active thyroid eye disease"],"prefix":"10.1038","volume":"36","author":[{"given":"Caroline Y.","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany A.","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chau M.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin M.","family":"Shriver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"key":"1904_CR1","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1038\/s41433-020-01297-w","volume":"35","author":"S Ugradar","year":"2020","unstructured":"Ugradar S, Shi L, Wang Y, Mester T, Yang H, Douglas RS. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression. Eye. 2020;35:2607\u201312.","journal-title":"Eye"},{"key":"1904_CR2","doi-asserted-by":"publisher","unstructured":"Ugradar S, Kang J, Kossler AL, Zimmerman E, Braun J, Harrison AR, et al. Teprotumumab for the treatment of chronic thyroid eye disease. Eye. (2021). https:\/\/doi.org\/10.1038\/s41433-021-01593-z.","DOI":"10.1038\/s41433-021-01593-z"},{"key":"1904_CR3","doi-asserted-by":"publisher","first-page":"100744","DOI":"10.1016\/j.ajoc.2020.100744","volume":"19","author":"DJ Ozzello","year":"2020","unstructured":"Ozzello DJ, Kikkawa DO, Korn BS. Early experience with teprotumumab for chronic thyroid eye disease. Am J Ophthalmol Case Rep. 2020;19:100744.","journal-title":"Am J Ophthalmol Case Rep."},{"key":"1904_CR4","doi-asserted-by":"publisher","unstructured":"Ozzello DJ, Dallalzadeh LO, Liu CY Teprotumumab for chronic thyroid eye disease. Orbit. (2021). https:\/\/doi.org\/10.1080\/01676830.2021.1933081.","DOI":"10.1080\/01676830.2021.1933081"},{"key":"1904_CR5","unstructured":"Sears CM, Amarikwa L, Men C, Shinder R, Clauss K, Ugrader S, et al. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease. Podium presentation at: ASOPRS 52nd Annual Fall Scientific Symposium; 2021 Nov 11\u201312; New Orleans, LA."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01904-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01904-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01904-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T14:15:21Z","timestamp":1656080121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01904-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":5,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1904"],"URL":"https:\/\/doi.org\/10.1038\/s41433-021-01904-4","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"assertion":[{"value":"7 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EMS is a Consultant\/Advisor for Horizon Therapeutics. The other authors have no financial or other conflicts of interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Consent to publish patient images has been obtained from the patient in writing.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}